['schizophrenia', 'schizo-affective disorder']
['risperidone implant']

        Inclusion Criteria:

          1. Subject (and/or a subject's authorized legal representative) has provided written
             informed consent

          2. Patient meets the following criteria:

               -  Outpatient status

               -  PANSS Total Score ≤ 80 at screening and if PANSS score at baseline is ≥ 20%
                  change from screening, the patients cannot participate in the study.

               -  A score of ≤ 3 on the following PANSS items:

                    -  Conceptual disorganization

                    -  Suspiciousness

                    -  Hallucinatory behavior

                    -  Unusual thought content

          3. Subject is male or female between 18 to 60 years of age

          4. Subject has a diagnosis of schizophrenia or schizoaffective disorder according to
             Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria

        Exclusion Criteria:

          1. Hospitalized or required acute crisis intervention for symptom exacerbation in the 60
             days prior to admission as determined by the Investigator

          2. Subject has a history of suicide attempt in the last year, or in the opinion of the
             investigator is currently at imminent risk of suicide

          3. Has a current or recent (within 12 months) DSM-V diagnosis of moderate or severe
             substance use disorder (except for tobacco use disorder) or has a positive urine drug
             screen for prohibited substances at screening.

          4. Have impaired hepatic (ALT/AST >1.5 times higher than the upper limit of normal) or
             renal function (eGFR<50 mL/min)

          5. Previously defined hypersensitivity to Risperidone

          6. History of neuromalignant syndrome (NMS)

          7. Electroconvulsive therapy within 6 months of admission

          8. Requires current use of agents that are strong inhibitors and inducers of cytochrome
             P450 2D6
      